An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

Leveraging lung cancer screening can improve chronic obstructive pulmonary disease detection and intervention in underserved populations.

Lung cancer may not be the most common cancer diagnosis in the United States—that would be prostate cancer for men and breast cancer for women—but it is by far the leading cause of cancer death in the country,

When Garen was diagnosed with lung cancer, biomarker testing helped focus his treatment options, inform his treatment decisions, and finding the appropriate treatment has allowed him to maintain his active lifestyle.

Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung cancer

Amgen AMGN announced that the European Commission (“EC”) has approved Imdylltra (tarlatamab) to treat adults with extensive-stage small cell lung cancer (“SCLC”) who require systemic therapy following disease progression on or after first-line platinum-based chemotherapy.

A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype of early-stage non-small cell lung cancer (NSCLC),